A detailed history of Mariner, LLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Mariner, LLC holds 14,086 shares of LYEL stock, worth $9,155. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,086
Previous 99,308 85.82%
Holding current value
$9,155
Previous $143,000 86.71%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1.13 - $1.88 $96,300 - $160,217
-85,222 Reduced 85.82%
14,086 $19,000
Q2 2024

Aug 13, 2024

SELL
$1.3 - $3.01 $8,104 - $18,764
-6,234 Reduced 5.91%
99,308 $143,000
Q1 2024

May 15, 2024

SELL
$1.71 - $3.07 $16,009 - $28,741
-9,362 Reduced 8.15%
105,542 $235,000
Q4 2023

Feb 14, 2024

BUY
$1.39 - $2.35 $49,507 - $83,699
35,617 Added 44.92%
114,904 $222,000
Q3 2023

Nov 13, 2023

BUY
$1.45 - $3.35 $52,678 - $121,705
36,330 Added 84.57%
79,287 $116,000
Q2 2023

Aug 11, 2023

BUY
$1.89 - $3.86 $14,192 - $28,984
7,509 Added 21.18%
42,957 $136,000
Q1 2023

May 12, 2023

BUY
$1.97 - $3.58 $49,768 - $90,441
25,263 Added 248.04%
35,448 $84,000
Q4 2022

Feb 14, 2023

BUY
$2.78 - $8.09 $28,314 - $82,396
10,185 New
10,185 $35,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $161M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Mariner, LLC Portfolio

Follow Mariner, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.